Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6749028 | 0.95 | MAPK1 (0.38) | SLC6A2SLC6A4SLC6A3KCNH2CHRNB2 | |
| SCHEMBL21220415 | 0.95 | MAPK1 (0.38) | SLC6A2SLC6A4SLC6A3KCNH2CHRNB2 | |
| SCHEMBL1706254 | 0.90 | YTHDF2 (0.33) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL9115684 | 0.84 | KMT2A (0.33) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL10659466 | 0.82 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3KCNH2KDM4E | |
| SCHEMBL6750420 | 0.82 | DRD2 (0.41) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL12243196 | 0.79 | — | — | |
| SCHEMBL14529580 | 0.78 | DRD2 (0.46) | — | |
| SCHEMBL14529344 | 0.76 | NSD2 (0.37) | ADORA2AADORA2BALDH1A1 | |
| SCHEMBL14529345 | 0.76 | DRD2 (0.45) | ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2228364-A1 | Acylsulfonamides as inhibitors of steroid sulfatase | Novartis AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-20090227620-A1 | ANTI-INFLAMMATORY COMPOUNDS | MEINGASSNER JOSEF GOTTFRIED | 2009-09-10 | — | — | US | disclosed |
| US-7482462-B2 | Acylsulfonamides as inhibitors of steroid sulfatase | NOVARTIS AG (CH) | 2009-01-27 | — | — | US | disclosed |
| US-20080293758-A1 | Combination of a Steroid Sulfatase Inhibitor and an Ascomycin | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
| EP-1861098-A1 | ANTI-INFLAMMATORY COMPOUNDS | Novartis AG (CH) | 2007-12-05 | — | — | EP | disclosed |
| EP-1861099-A2 | COMBINATION OF A STEROID SULFATASE INHIBITOR AND AN ASCOMYCIN | Novartis AG (CH) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006097293-A2 | COMBINATION OF A STEROID SULFATASE INHIBITOR AND AN ASCOMYCIN | NOVARTIS AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006097292-A1 | ANTI-INFLAMMATORY COMPOUNDS | NOVARTIS AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| US-20050059712-A1 | Acylsulfonamides as inhibitors of steroid sulfatase | NOVARTIS AG (CH) | 2005-03-17 | — | — | US | disclosed |
| EP-1436253-A1 | ACYLSULFONAMIDES AS INHIBITORS OF STEROID SULFATASE | Novartis AG (CH) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003031397-A1 | ACYLSULFONAMIDES AS INHIBITORS OF STEROID SULFATASE | NOVARTIS AG (CH) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293758-A1 | Combination of a Steroid Sulfatase Inhibitor and an Ascomycin | STS, ARSA, CYP17A1 | SLC6A2 1415/4885SLC6A4 1546/4885SLC6A3 1919/4885 |
| US-20090227620-A1 | ANTI-INFLAMMATORY COMPOUNDS | STS, SERPINB1, MPO | SLC6A2 3110/4885SLC6A4 2811/4885SLC6A3 3765/4885 |
| US-20050059712-A1 | Acylsulfonamides as inhibitors of steroid sulfatase | STS, SULT2A1, ARSA | SLC6A2 2252/4885SLC6A4 1126/4885SLC6A3 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.